BioSpace News Archive

Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company’s operational and clinical activities.

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom

Novo Nordisk announced the European Commission has granted marketing authorization for Rybelsus®,, for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycemic control as an adjunct to diet and exercise.

Emmes announced that Heather Hill, Dr. Adam Mendizabal and Dr. Nilay Shah have been promoted to vice president.

ProtoKinetix, Incorporated (ecently announced filing for patent protection for new applications of its AAGP® (PKX-001) molecule, announces preliminary results in efficacy and safety for use in treating Dry Eye Disease (DED).

In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the “Company”) (NASDAQ:LNTH) has determined to change the format of the company’s 2020 Annual Meeting of Stockholders scheduled for Thursday, April 23, 2020 at 11:00 a.m. (Eastern Time) from in-person to virtual-only.

Cerus Corporation (Nasdaq:CERS) today announced the Company’s recent activities related to COVID-19 and efforts to ensure that patients have readily available access to pathogen-reduced blood components, including convalescent plasma. “As the world endures the impact from the current COVID-19 pandemic, our focused mission of ensuring the availability and safety of the world’s blood supply has never been more relevan

Matt Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE:IVC), will participate in a fireside chat at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020 at 9:20 a.m. ET

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in April. Management presentation details are as follows:

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), today announced that it has entered into an agreement with Sleep Data Diagnostics and its virtual-care platform BetterNight and Sleep Data Holdings, a leading provider of home-based positive airway pressure (PAP) services.